Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paolo Vigneri

Showing results (141-150 of 150) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 150 results.
Neoplasia (New York, N.Y.)|September 24, 2016
Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid LeukemiaRoberto Latagliata, Fabio Stagno, Mario Annunziata, et al.
American Journal of Hematology|October 23, 2016
A population-based study of chronic myeloid leukemia patients treated with imatinib in first lineFausto Castagnetti, Francesco Di Raimondo, Antonio De Vivo, et al.
Nature Communications|August 19, 2021
Adipose stem cell niche reprograms the colorectal cancer stem cell metastatic machinerySimone Di Franco, Paola Bianca, Davide Stefano Sardina, et al.
Leukemia|June 8, 2022
Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapyMatthew Salmon, Helen E White, Hana Zizkova, et al.
Nature Communications|June 24, 2026
Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world studyDavide Massa, Theodoros Foukakis, Sylvie Giacchetti, et al.
Blood Cancer Discovery|September 25, 2020
Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on <i>MIR300</i> Antiproliferative and PP2A-Activating FunctionsGiovannino Silvestri, Rossana Trotta, Lorenzo Stramucci, et al.
Oncotarget|September 1, 2016
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcomeAlessandra Iurlo, Alessandro Nobili, Roberto Latagliata, et al.
Blood|December 27, 2019
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML studySimona Soverini, Luana Bavaro, Caterina De Benedittis, et al.
Blood Advances|December 24, 2019
Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WPMichele Baccarani, Elisabetta Abruzzese, Vincenzo Accurso, et al.
Leukemia|May 25, 2022
Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome studyHelen E White, Matthew Salmon, Francesco Albano, et al.
Pageof 15

Showing results (141-150 of 150) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 150 results.
Neoplasia (New York, N.Y.)|September 24, 2016
Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid LeukemiaRoberto Latagliata, Fabio Stagno, Mario Annunziata, et al.
American Journal of Hematology|October 23, 2016
A population-based study of chronic myeloid leukemia patients treated with imatinib in first lineFausto Castagnetti, Francesco Di Raimondo, Antonio De Vivo, et al.
Nature Communications|August 19, 2021
Adipose stem cell niche reprograms the colorectal cancer stem cell metastatic machinerySimone Di Franco, Paola Bianca, Davide Stefano Sardina, et al.
Leukemia|June 8, 2022
Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapyMatthew Salmon, Helen E White, Hana Zizkova, et al.
Nature Communications|June 24, 2026
Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world studyDavide Massa, Theodoros Foukakis, Sylvie Giacchetti, et al.
Blood Cancer Discovery|September 25, 2020
Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on <i>MIR300</i> Antiproliferative and PP2A-Activating FunctionsGiovannino Silvestri, Rossana Trotta, Lorenzo Stramucci, et al.
Oncotarget|September 1, 2016
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcomeAlessandra Iurlo, Alessandro Nobili, Roberto Latagliata, et al.
Blood|December 27, 2019
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML studySimona Soverini, Luana Bavaro, Caterina De Benedittis, et al.
Blood Advances|December 24, 2019
Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WPMichele Baccarani, Elisabetta Abruzzese, Vincenzo Accurso, et al.
Leukemia|May 25, 2022
Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome studyHelen E White, Matthew Salmon, Francesco Albano, et al.
Pageof 15